A computer simulation model of diabetes progression, quality of life, and cost

Diabetes Care

Volumn 28, Issue 12, 2005, Pages 2856-2863

  Zhou, Honghong ^a   Isaman, Deanna J M ^a   Messinger, Shari ^a   Brown, Morton B ^a   Klein, Ronald ^b   Brandle, Michael ^c,d   Herman, William H ^c,d,e  

^a UNIVERSITY OF MICHIGAN SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

^e UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; COST UTILITY ANALYSIS; DIABETIC RETINOPATHY; DISEASE COURSE; HEART INFARCTION; HUMAN; INCIDENCE; INSURANCE; KIDNEY FAILURE; MICROALBUMINURIA; MORBIDITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; PROLIFERATIVE RETINOPATHY; PROTEINURIA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SIMULATION; STROKE; SURVIVAL; BIOLOGICAL MODEL; COMPUTER SIMULATION; COST; DIABETES MELLITUS; ECONOMICS; FEMALE; MALE; PATHOPHYSIOLOGY; PSYCHOLOGICAL ASPECT; RACE; UNITED STATES;

COMPUTER SIMULATION; CONTINENTAL POPULATION GROUPS; COSTS AND COST ANALYSIS; DIABETES COMPLICATIONS; DIABETES MELLITUS; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MICHIGAN; MODELS, BIOLOGICAL; WISCONSIN;

EID: 33644830928     PISSN: 01495992     EISSN: 01495992     Source Type: Journal    
DOI: 10.2337/diacare.28.12.2856     Document Type: Article

References (37)

1. U.S. Department of Health and Human Services, Division of Diabetes Translation: Diabetes Surveillance, 1997. Atlanta, GA, Centers for Disease Control and Prevention, 1997
2. Geiss LS, Herman WH, Smith PJ: Mortality in non-insulin-dependent diabetes. In Diabetes in America. 2nd ed. Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 1995 (NIH publ. no. 95-1468)
3. Brown JB, Russell A, Chan W, Pedula K, Aickin M: The global diabetes model: user friendly version 3.0. Diabetes Res Clin Pract 50 (Suppl. 3):S15-S46, 2000
4. Palmer AJ, Brandt A, Gozzoli V, Weiss C, Stock H, Wenzel H: Outline of a diabetes disease management model: principles and applications. Diabetes Res Clin Pract 50 (Suppl. 3):S47-S56, 2000
5. CDC Diabetes Cost-Effectiveness Group: Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. JAMA 287:2542-2551, 2002
6. Eddy DM, Schlessinger L: Archimedes: a trial-validated model of diabetes. Diabetes Care 26:3093-3101, 2003
7. Clarke PM, Gray AM, Briggs A, Farmer A, Fenn P, Stevens R, Matthews D, Stratton IM, Holman R: A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS 68). Diabetologia 47:1747-1759, 2004
8. Klein R, Klein BEK, Moss SE, Davis MD, DeMets DL: The Wisconsin Epidemiologic Study of Diabetic Retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmol 102:527-532, 1984
9. National Center for Health Statistics: 1993 abridged life table and 1998 life table [article online]. Available at http://www.cdc.gov/nchs/data/ lifetables/life93_2.pdf and http://www.cdc.gov/nchs/data/series/sr_02/sr02_129. pdf
10. Harris MI, Flegal KM, Cowie CC, Eberhardt MS, Goldstein De, Little RR, Wiedmeyer HM, Byrd-Holt DD: Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults: the third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care 21:518-524, 1998
11. Edelstein SL, Knowler WC, Bain RP, Andres R, Barrett-Connor EL, Dowse GK, Haffner SM, Pettitt DJ, Sorkin JD, Muller DC, Collins VR, Hamman RF: Predictors of progression from impaired glucose tolerance to NIDDM: an analysis of six prospective studies. Diabetes 46:701-710, 1997
12. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853, 1998
13. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL: The Wisconsin Epidemiologic Study of Diabetic Retinopathy. X. Four-year incidence and progression of diabetic retinopathy when age at diagnosis 30 years or more. Arch Ophthalmol 107:244-249, 1989
14. Klein R, Klein BE, Moss SE, Cruickshanks KJ: The Wisconsin Epidemiologic Study of diabetic retinopathy. XIV. Ten-year incidence and progression of diabetic retinopathy. Arch Ophthalmol 112:1217-1228, 1994
15. Klein R, Klein BE, Moss SE, Cruickshanks KJ: The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XV. The long-term incidence of macular edema. Ophthalmology 102:7-16, 1995
16. Moss SE, Klein R, Klein BE: The incidence of vision loss in a diabetic population. Ophthalmology 95:1340-1348, 1988
17. Moss SE, Klein R, Klein BE: Ten-year incidence of visual loss in a diabetic population. Ophthalmology 101:1061-1070, 1994
18. Gall MA, Hougaard P, Borch-Johnsen K, Parving HH: Risk factors for development of incipient and overt diabetic nephropathy in patients with non-insulin dependent diabetes mellitus: prospective, observational study. BMJ 314:783-788, 1997
19. Ballard DJ, Humphrey LL, Melton LJ 3rd, Frohnert PP, Chu PC, O'Fallon WM, Palumbo PJ: Epidemiology of persistent proteinuria in type II diabetes mellitus: population-based study in Rochester, Minnesota. Diabetes 37:405-412, 1998
20. Ravid M, Savin H, Jutrin I, Bental T, Katz B, Lishner M: Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 118:577-581, 1993
21. United States Renal Data System: Incidence of Reported ESRD, 2000. Annual report. Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2000 (Section A:247-294)
22. United States Renal Data System: Incidence of Reported ESRD, 2000. Annual report. Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2000 (Section F:495-550)
23. United States Renal Data System: Incidence of Reported ESRD, 2000. Annual report. Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2000 (Section H:581-684)
24. Sands ML, Shetterly SM, Franklin GM, Hamman RF: Incidence of distal symmetric (sensory) neuropathy in NIDDM: the San Luis Valley Diabetes Study. Diabetes Care 20:322-329, 1997
25. Adler AI, Boyko EJ, Ahroni JH, Smith DG: Lower-extremity amputation in diabetes: the independent effects of peripheral vascular disease, sensory neuropathy, and foot ulcers. Diabetes Care 22:1029-1035, 1999
26. Malmberg K, Yusuf S, Gerstein HC, Brown J, Zhao F, Hunt D, Piegas L, Calvin J, Keltai M, Budaj A: Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) registry. Circulation 102:1014-1019, 2000
27. Ulvenstam G, Aberg A, Bergstrand R, Johansson S, Pennert K, Vedin A, Wilhelmsen L, Wilhelmsson C: Long-term prognosis after myocardial infarction in men with diabetes. Diabetes 34:787-792, 1985
28. Lowel H, Koenig W, Engel S, Hormann A, Keil U: The impact of diabetes mellitus on survival after myocardial infarction: can it be modified by drug treatment? Results of a population-based myocardial infarction register follow-up study. Diabetologia 43:218-226, 2000
29. Miettinen H, Lehto S, Salomaa V, Mahonen M, Niemela M, Haffner SM, Pyorala K, Tuomilehto J: Impact of diabetes on mortality after the first myocardial infarction. Diabetes Care 21:69-75, 1998
30. Stevens RJ, Kothari V, Adler AI, Stratton IM: The UKPDS risk engine: a model for the risk of coronary heart disease in type II diabetes (UKPDS 56). Clin Sci (Lond) 101:671-679, 2001
31. Hier DB, Foulkes MA, Swiontoniowski M, Sacco RL, Gorelick PB, Mohr JP, Price TR, Wolf PA: Stroke recurrence within 2 years after ischemic infarction. Stroke 22:155-161, 1991
32. Sacco RL, Shi T, Zamanillo MC, Kargman DE: Predictors of mortality and recurrence after hospitalized cerebral infarction in an urban community: the Northern Manhattan Stroke Study. Neurology 44:626-634, 1994
33. Coffey JT, Brandle M, Zhou H, Marriott D, Burke R, Tabaei BP, Engelgau MM, Kaplan RM, Herman WH: Valuing healthrelated quality of life in diabetes. Diabetes Care 25:2238-2243, 2002
34. Brandle M, Zhou H, Smith BRK, Marriott D, Burke R, Tabaei BP, Brown MB, Herman WH: The direct medical cost of type 2 diabetes. Diabetes Care 26:2300-2304, 2003
35. American Diabetes Association: Standards of medical care for patients with diabetes mellitus (Position Statement). Diabetes Care 28 (Suppl. 1):S4-S36, 2005
36. Herman WH: Diabetes modeling. Diabetes Care 26:3182-3183, 2003
37. Kothari V, Stevens RJ, Adler AI, Stratton IM, Manley SE, Neil HA, Holman RR: Risk of stroke in type 2 diabetes estimated by the UK Prospective Diabetes Study risk engine (UKPDS 60). Stroke 33:1776-1781, 2002